021-51111890
购物车（0）
sales@molnova.cn
SKL2001
CAS No. 909089-13-0
SKL2001 ( SKL 2001 | SKL-2001 )
产品货号. M16533 CAS No. 909089-13-0
SKL2001 是 Wnt/β-catenin 通路的特异性小分子激活剂（激动剂）。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥275 | 有现货 |
|
| 10MG | ￥446 | 有现货 |
|
| 25MG | ￥883 | 有现货 |
|
| 50MG | ￥1580 | 有现货 |
|
| 100MG | ￥2892 | 有现货 |
|
| 200MG | ￥4350 | 有现货 |
|
| 500MG | ￥6796 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称SKL2001
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述SKL2001 是 Wnt/β-catenin 通路的特异性小分子激活剂（激动剂）。
-
产品描述SKL2001 is a specific small molecule activator (agonist) of the Wnt/β-catenin pathway, stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction; strongly activates β-catenin responsive transcription, upregulates TOPflash reporter activity without effect on the activity of FOPFlash with mutated β-catenin/Tcf-binding elements, as well as either NF-κB or p53 reporter activity; upregulates the expression of Axin2, inhibits N-terminal β-catenin phosphorylation without affecting GSK-3β activity; suppresses preadipocyte differentiation, the alternative mesenchymal differentiation pathway.(In Vitro):SKL2001 is an agonist of the Wnt/β-catenin pathway, and also upregulates the expression of Axin2, a downstream target of the Wnt/β-catenin pathway, but shows no effect on NF-κB, p53 reporter activity and GSK-3β activity. SKL2001 causes osteoblast differentiation (20 and 40 μM) and suppresses preadipocyte differentiation (5, 10, and 30 μM) via the activation of the Wnt/β-catenin pathway. SKL2001 (5, 10, and 30 μM) stabilizes intracellular β-catenin in 3T3-L1 cells. SKL2001 (40 μM) significantly inhibits the proliferation of HCT116 spheroids independently of cytotoxicity and the inhibition is reversible; SKL2001 cuases cell cycle arrest in HCT116 spheroids. SKL2001 (40 μM) enhances round-shape spheroid formation and E-cadherin expression.
-
体外实验SKL2001 is an agonist of the Wnt/β-catenin pathway, and also upregulates the expression of Axin2, a downstream target of the Wnt/β-catenin pathway, but shows no effect on NF-κB, p53 reporter activity and GSK-3β activity. SKL2001 causes osteoblast differentiation (20 and 40 μM) and suppresses preadipocyte differentiation (5, 10, and 30 μM) via the activation of the Wnt/β-catenin pathway. SKL2001 (5, 10, and 30 μM) stabilizes intracellular β-catenin in 3T3-L1 cells. SKL2001 (40 μM) significantly inhibits the proliferation of HCT116 spheroids independently of cytotoxicity and the inhibition is reversible; SKL2001 cuases cell cycle arrest in HCT116 spheroids. SKL2001 (40 μM) enhances round-shape spheroid formation and E-cadherin expression.
-
体内实验——
-
同义词SKL 2001 | SKL-2001
-
通路Wnt/Notch/Hedgehog
-
靶点Beta-catenin
-
受体Wnt/β-catenin
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number909089-13-0
-
分子量286.291
-
分子式C14H14N4O3
-
纯度>98% (HPLC)
-
溶解度DMSO: 53 mg/mL (185.1 mM); Ethanol: 53 mg/mL (185.1 mM); Water: <1 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESO=C(C1=NOC(C2=CC=CO2)=C1)NCCCN3C=CN=C3
-
化学全称5-Furan-2yl-isoxazole-3-carboxylic acid (3-imidazol-1yl-propyl)-amide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Gwak J, et al. Cell Res. 2012 Jan;22(1):237-47.
2. DiRenzo DM, et al. Cell Signal. 2016 May;28(5):498-505.
3. Ohashi W, et al. Biochem Biophys Res Commun. 2017 Nov 25;493(3):1342-1348.
